Skip to contents
Investment funds

It seems strange that in this day and age there are more than 7,000 rare diseases.

Biotechnology
biotecnologia_superior
Categoría
Investment funds
Tipo de contenido
Actualidad
Tiempo de lectura
minutos
Publicado
20 Oct 2022
In the same way that it can be strange to talk about something as complex as the biotech industry. However, its application in the medical and pharmaceutical sector is of vital importance for the development of modern medicine, being vital for more than 300 million people who are waiting for a cure.
  • Biotechnology provides new solutions for the diagnosis and treatment of diseases.
    Biotechnology uses biological systems, living organisms and derivatives capable of offering new, more complex and effective treatments.
  • The power of the biotechnology industry in the pharmaceutical sector.
    The products of biotechnology companies currently account for seven out of ten of the world's best-selling medicines.
  • A population that is increasing in number and age.
    A trend that continues to grow and that will require a greater number of diagnoses and medical treatments.
central_biotechnology
The ageing of the population and demographic changes are realities that make biotechnology an investment trend.
The combination of greater longevity together with the increase in the population means that there is an increasing demand for medicines and, consequently, an increase in the income of companies in the sector.
  • An increasingly ageing population.
    Projections indicate that by 2050, the population over 60 years of age will have doubled.
  • The older the population, the higher the consumption of medicines.
    From the age of 60, the consumption of medicines is 2.5 times greater than that of a young person and even more relevant: from the age of 80, the figure is multiplied by nine.

Projection of the world population over 60 years of age.


Health spending increases with age


Source: Candriam, United Nations and Canadian Institute for Health Information.
A sector that essentially depends on the approval of new medicines.
And to this end, new drug research and the added value they provide are essential.
  • It is estimated that 300 million people in the world are affected by the 7,000 rare diseases that have been identified.
    But the most significant fact is: 95% of these diseases do not have an approved drug for their treatment.
  • 54.5 million people currently suffer from arthritis.
    One in four Americans suffers from this disease, almost the equivalent of the entire population residing in Italy.

Investment in health: a fundamental aspect for the economic and social growth of the countries.

  • The higher the GDP, the higher the investment in health.
    For example, In the USA , per capita spending on health is 17 times greater than in China, although these differences will tend to narrow as the countries' per capita income increases.
  • The engine of emerging countries.
    Globally, spending in the biotech sector is expected to grow by 10% per year until 2026.
lower_nutrition

Source: IQVIA Institute, Nov 2021

The investment universe is based around globally listed companies focused on the biotech sector and offering exposure to cutting-edge biotech companies working on drug development and molecular diagnostics.

  • Phase II drug development.
    That is, those that begin to show the first signs of efficiency in humans before taking a position in companies.
  • Equipment and supplies.
    Within the industry, investments are made in medical equipment and supply companies, medical service providers, pharmaceuticals, and tools and services for the health sciences.

What do the experts think?

  • It's a sector that is less sensitive to economic cycles because healthcare isn't correlated with the market.
  • It has the ability to set prices and therefore adapts better to inflationary periods like the present one.
  • It's market that is currently trading well below its historical valuations and the general market.

Our investment proposal

Invest in funds through shares in infrastructure corporates around the globe.

The value of investment funds1 can fall as well as rise, and you may get back less than you invested.


ISIN
Fund
Risk profile
Issuance
Fees2
Minimum contribution
Fact sheet/Subscribe
LU1120766388
CANDRIAM EQUITIES L BIOTECHNOLOGY "C" (EUR) ACC
Very high
EUR
1,50%
1000 €
LU0255977455
PICTET BIOTECH "P" (EUR) ACC
Very high
EUR
1,60%
1000 €
LU0415392249
BELLEVUE BIOTECH "B" (EUR) ACC
Advanced
EUR
1,60%
1000 €